Athera Biotechnologies AB today announced that all follow-up visits (12 weeks after last dosing) in a multiple dosing study in healthy volunteers with its fully human antibody PC-mAb have been completed. Positive preliminary safety and pharmacokinetics data provides continued support for further clinical development with once monthly administrations.
“We are very happy with the preliminary data of this study which supports our development plans and the upcoming initiation of the Phase 2a study”, says Carina Schmidt, CEO of Athera.
The fully human PC-mAb is designed to mimic the anti-inflammatory role of endogenous antibodies against PC, and act to support the immune response to vascular inflammation challenges, and thereby reduce the risk for complications.
For more information, contact: Carina Schmidt, CEO, Athera Biotechnologies AB Phone: +46 (0)76 1938 190, email: c.schmidt@athera.se
About Athera Biotechnologies AB
The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of immunovascular disease. Athera´s focus is on PC-mAb, a clinical stage biopharmaceutical program with block-buster potential. Development of PC-mAb has been co-funded by EU FP7 in the CARDIMMUN project. Major shareholders are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB.For more information: [www.athera.se](http://www.athera.se/)
